- Home
- OABI vs ABEO Comparison
OABI vs ABEO Comparison
Compare OABI & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OABI | ABEO |
|---|---|---|
| Founded | 2012 | 1974 |
| Country | United States | United States |
| Employees | 89 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.4M | 399.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | OABI | ABEO |
|---|---|---|
| Price | $1.98 | $5.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.50 | ★ $20.00 |
| AVG Volume (30 Days) | 479.5K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | $52.42 | $1,024.31 |
| Revenue Next Year | $64.69 | $145.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $1.32 | $4.00 |
| 52 Week High | $2.79 | $7.54 |
Technical Indicators
Market Signals| Indicator | OABI | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 36.49 | 41.56 |
| Support Level | $1.75 | $4.85 |
| Resistance Level | $2.08 | $6.01 |
| Average True Range (ATR) | 0.14 | 0.37 |
| MACD | -0.02 | -0.14 |
| Stochastic Oscillator | 5.00 | 9.15 |
Price Performance
Historical ComparisonAbout OABI OmniAb Inc.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.